索利那新治疗儿童和青少年膀胱过度活动症的长期安全性和有效性
本研究为一项为期12周的双盲安慰剂对照试验的40周开放标签扩展研究,评估每日一次口服索利那新混悬液在5至不足12岁儿童和12至不足18岁青少年膀胱过度活动症患者中的长期安全性和有效性。共纳入119名儿童和29名青少年。药物相关治疗中出现的不良事件发生率儿童为34.7%、青少年为37.9%,最常见分别为便秘和心电图QT间期延长。所有疗效参数在第3周观察到的改善在研究期间进一步改善和/或维持。
要点
- 索利那新口服混悬液在儿童和青少年膀胱过度活动症患者中耐受性良好,最长可达52周。
- 儿童最常见药物相关不良事件为便秘(11.9%)、心电图QT间期延长(8.5%)和口干(4.2%)。
- 青少年最常见药物相关不良事件为心电图QT间期延长(13.8%)和恶心(6.9%)。
核心结论
- 每日一次索利那新口服混悬液在5至不足12岁儿童和12至不足18岁青少年膀胱过度活动症患者中耐受性良好,最长可达52周,儿童和青少年最常见的不良反应分别为便秘和心电图QT间期延长。
- 第3周观察到的疗效改善在研究期间得以维持。
研究设计与样本
- 研究为一项12周双盲、安慰剂对照试验的40周开放标签扩展研究。
- 共纳入119名儿童(5至不足12岁)和29名青少年(12至不足18岁)膀胱过度活动症患者。
- 主要终点为不良事件的发生率和严重程度。
主要发现
- 药物相关治疗中出现的不良事件发生率儿童为34.7%,青少年为37.9%。
- 儿童中最常见的药物相关治疗中出现的不良事件为便秘(11.9%)、心电图QT间期延长(8.5%)和口干(4.2%)。
- 青少年中最常见的药物相关治疗中出现的不良事件为心电图QT间期延长(13.8%)和恶心(6.9%)。
- 因不良事件导致停药的比例儿童为10.2%,青少年为13.8%。
- 未发生尿潴留或排尿后残余尿量增加,实验室变量或生命体征无临床相关变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the long-term safety and efficacy of once daily oral solifenacin suspension in children (5 to less than 12 years old) and adolescents (12 to less than 18 years old) with overactive bladder. MATERIALS AND METHODS: We conducted a 40-week, open label extension of a 12-week double-blind, placebo controlled trial. Outcome measures included incidence and severity of adverse events (primary end point), laboratory variables, vital signs, 12-lead electrocardiogram, post-void residual volume, and change from baseline to end of treatment in mean number of micturitions and incontinence episodes per 24 hours, number of incontinence-free days per 7 days and number of grade 3 or 4 urgency episodes per 24 hours (adolescents only). RESULTS: A total of 119 children and 29 adolescents were enrolled in the study. The incidence of drug related treatment emergent adverse events was 34.7% (children) and 37.9% (adolescents), the most common of which were constipation (11.9%), electrocardiogram QT prolonged (8.5%) and dry mouth (4.2%) in children, and electrocardiogram QT prolonged (13.8%) and nausea (6.9%) in adolescents. Adverse events resulted in 10.2% (children) and 13.8% (adolescents) of participants discontinuing treatment. There were no cases of urinary retention or increases in post-void residual volume and no clinically relevant changes in laboratory variables or vital signs. Two cases of dizziness but no other central nervous system drug related treatment emergent adverse events were reported. Improvements in all efficacy parameters and grade 3 or 4 urgency episodes observed by 3 weeks were further improved and/or maintained during the study. CONCLUSIONS: Once daily solifenacin oral suspension was well tolerated for up to 52 weeks in children 5 to less than 12 years old and adolescents 12 to less than 18 years old diagnosed with overactive bladder, with constipation and electrocardiogram QT prolonged as the most common adverse reactions, respectively. Improvements in efficacy at 3 weeks were sustained during the study.
引用
- Newgreen D, Bosman B, Hollestein-Havelaar A, et al. Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder. J Urol. 2017. PMID: 28506854. doi:10.1016/j.juro.2017.05.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。